SGMOQ · Sangamo Therapeutics, Inc · Share Buybacks
$0.15
+0.00 (+1.51%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of significant losses, negative cash flows from operations, negative working capital, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management's assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued.”View the 10-Q filed May 14, 2026
Market Cap
$58.00M
Shares
414.29M
Volume · Oct 2
1.6M
Avg daily vol (3M)
2.74M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| — | — | $325,000,000 | $129,500,000 as of 2026-03-31 | — | 10-Q , filed 2026-05-14 |